Baxdela is your Path Forward.

Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your path forward.

aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).

Pathway to Efficacy

Diabetes, age, obesity—multiple factors impact ABSSSI treatment.

See Baxdela Results

Explore Safety
& Tolerability

See Baxdela Outcomes

Simplify Dosing & Administration

Straightforward dosing in IV, oral, or IV to oral.

See Baxdela Options

Pathway to
Pathogen Coverage

Microbiological activity against susceptible gram-negative and gram-positive pathogens, including MRSA.

See Response Rates

Simplify
Patient Access

For hospital or home, streamline access with MelintAssist.

Explore Baxdela Options

Next: Introduction

Melinta Therapeutics, Inc. - The Antibiotics Company

For additional information about BAXDELA, call Melinta Therapeutics at 1-844-MED-MLNT (1-844-633-6568) or contact the US Food and Drug Administration at 1-888-INFO-FDA (1-888-463-6332).

©2018 All rights reserved PP-BAX-US-0399 v1.0 Terms of Use

BAXDELA™ is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.